Since their transition from small, academic clinical trials to commercial production, CAR-T cell therapies have won recognition as a novel and highly effective therapeutic modality, particularly in ...

This month, Tmunity Therapeutics is dosing the first patients who have enrolled in an early clinical trial testing an engineered CAR-T immune cell therapy for metastatic prostate cancer. The trial's ...

After notching a handful of regulatory approvals in the last four years, chimeric antigen receptor (CAR) T-cell therapies are beginning to deliver remarkable efficacy for cancer patients—albeit with ...

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. CAR T cells are engineered cancer immunotherapies that boost or hijack a person’s immune system to ...

As the motoring world moves ever-closer to the welcome infiltration of electrically-powered cars, one thing holding them back is the availability of charging stations to “refuel” the vehicles which so ...

Precision BioSciences, one of the biotechs working with so-called off-the-shelf chimeric antigen receptor T-cell (CAR-T) therapies, last year bagged $110 million in a series B round. Some of that cash ...

KLN-1010 showed deep, ongoing MRD-negative responses in relapsed/refractory multiple myeloma with a favorable safety profile as an off-the-shelf product. The phase 1 inMMyCAR trial demonstrated ...

The most powerful force in medicine isn’t a wonder drug or next-generation surgical device. It’s the human immune system, which has evolved over millennia to be a central mediator of health. When it’s ...

CRISPR Therapeutics’ off-the-shelf CAR-T therapy has fallen short of the high bar set by investors, while still achieving a response in more than half of patients with B-cell cancers in the trial. The ...

Coverage from the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, Florida, featured results for allogeneic or "off the shelf" CAR T-cell treatments and bispecific ...